Yesterday, multiple media sources reported that AbbVie is stopping its phase 1 clinical trial of lemzoparlimab (“lemzo”) as part of a combination treatment for myelodysplastic syndromes, or MDS, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results